Results 71 to 80 of about 41,743 (197)
Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review
Case Reports in Rheumatology, 2019 Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation.
Georgio Medawar +2 more
doaj +1 more source
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Atherosclerosis is a chronic inflammatory disease of the blood vasculature. Endothelial dysfunction is an early event in the development of atherosclerosis and the endothelium plays an important role in the innate immune defense in the pathology of ...
Xiaoyang Yang +4 more
doaj +1 more source
Allergy, EarlyView.Staphylococcus aureus, commonly colonising CTCL patients, augments skin barrier dysfunction. Staphylococcal enterotoxins induce T‐cell release of barrier‐repressing cytokines (IL‐4, IL‐13, IL‐22, OSM). Cytokine signalling drives JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. Antibiotic‐mediated eradication of S. aureus induces
Maria Gluud +23 more
wiley +1 more source
Allergy, EarlyView.Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez +10 more
wiley +1 more source
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Arthritis Research & Therapy, 2018 Background Tofacitinib is the first oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA). We compared the effectiveness and safety of tofacitinib, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor ...
Marina Amaral de Ávila Machado +5 more
doaj +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Contact Dermatitis, EarlyView.Patch testing and repeated use (ROAT) with Lin‐OOH revealed dose‐dependent reactions in sensitised individuals. Lin‐OOH 1.0% was the most reliable patch test concentration to confirm CA in our cohort. Skin biopsy gene expression analysis shows upregulation of IL1β, IL4, GATA3 and CCL22, confirming activation of immune pathways consistent with fragrance
Sofia Botvid +8 more
wiley +1 more source
International Journal of Dermatology, EarlyView.A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair +17 more
wiley +1 more source